Vaxart Research Development vs Interest Expense Analysis

VXRT Stock

USD 0.61 0.01 1.67%

Vaxart financial indicator trend analysis is much more than just breaking down Vaxart Inc prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Vaxart Inc is a good investment. Please check the relationship between Vaxart Research Development and its Interest Expense accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vaxart Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

Research Development vs Interest Expense

Research Development vs Interest Expense Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Vaxart Inc Research Development account and Interest Expense. At this time, the significance of the direction appears to have almost no relationship.

The correlation between Vaxart's Research Development and Interest Expense is 0.17. Overlapping area represents the amount of variation of Research Development that can explain the historical movement of Interest Expense in the same time period over historical financial statements of Vaxart Inc, assuming nothing else is changed. The correlation between historical values of Vaxart's Research Development and Interest Expense is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Research Development of Vaxart Inc are associated (or correlated) with its Interest Expense. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Interest Expense has no effect on the direction of Research Development i.e., Vaxart's Research Development and Interest Expense go up and down completely randomly.

Correlation Coefficient

0.17

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Research Development

Interest Expense

The cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit.

Most indicators from Vaxart's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Vaxart Inc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vaxart Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

Enterprise Value is likely to gain to about 127.8 M in 2024, whereas Selling General Administrative is likely to drop slightly above 21.2 M in 2024.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	70.6M	110.4M	90.7M	95.3M
Cost Of Revenue	48.7M	3.3M	68.1M	53.4M

Total Operating Expenses Cost Of Revenue

Vaxart fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Intangible Assets	Accounts Payable	Common Stock Total Equity	Common Stock
Total Assets		0.21	0.29	0.45	0.98	0.57	-0.64	-0.53	0.82	0.68	0.39	0.9	-0.1	0.7	0.42	-0.18	0.8	0.73	0.65	0.48	0.85	0.27	0.09	0.04	-0.57	-0.41
Short Long Term Debt Total	0.21		-0.07	0.01	0.1	0.6	0.35	-0.69	-0.17	0.47	0.52	-0.01	-0.42	0.61	0.46	0.03	0.4	0.61	0.45	0.58	-0.11	0.56	-0.07	-0.2	-0.44	-0.35
Other Current Liab	0.29	-0.07		0.79	0.3	0.06	-0.24	0.02	0.26	0.07	-0.14	0.23	0.62	0.03	-0.3	-0.11	0.04	0.1	0.13	0.02	0.29	-0.04	-0.25	-0.24	-0.08	0.04
Total Current Liabilities	0.45	0.01	0.79		0.43	0.37	-0.19	-0.2	0.28	0.31	0.06	0.28	0.62	0.28	-0.24	-0.14	0.32	0.23	0.3	0.27	0.33	0.14	-0.2	0.22	-0.31	-0.23
Total Stockholder Equity	0.98	0.1	0.3	0.43		0.47	-0.73	-0.37	0.87	0.61	0.32	0.93	-0.01	0.6	0.26	-0.15	0.74	0.6	0.48	0.4	0.91	0.11	0.07	0.12	-0.54	-0.36
Property Plant And Equipment Net	0.57	0.6	0.06	0.37	0.47		0.16	-0.85	0.09	0.9	0.82	0.26	-0.31	0.92	0.49	0.21	0.72	0.85	0.68	0.87	0.19	0.72	0.07	0.02	-0.74	-0.66
Net Debt	-0.64	0.35	-0.24	-0.19	-0.73	0.16		-0.13	-0.95	0.0	0.28	-0.88	-0.13	0.0	-0.04	0.34	-0.24	-0.09	-0.14	0.12	-0.91	0.34	-0.01	-0.1	0.01	-0.13
Retained Earnings	-0.53	-0.69	0.02	-0.2	-0.37	-0.85	-0.13		-0.13	-0.73	-0.6	-0.26	0.4	-0.85	-0.75	0.13	-0.63	-0.95	-0.84	-0.83	-0.15	-0.83	-0.01	0.25	0.51	0.44
Cash	0.82	-0.17	0.26	0.28	0.87	0.09	-0.95	-0.13		0.24	-0.1	0.95	0.04	0.28	0.21	-0.33	0.47	0.35	0.36	0.13	0.94	-0.07	0.04	0.07	-0.22	-0.05
Non Current Assets Total	0.68	0.47	0.07	0.31	0.61	0.9	0.0	-0.73	0.24		0.76	0.38	-0.32	0.92	0.5	0.09	0.76	0.83	0.66	0.8	0.31	0.61	0.41	-0.1	-0.82	-0.83
Non Currrent Assets Other	0.39	0.52	-0.14	0.06	0.32	0.82	0.28	-0.6	-0.1	0.76		0.16	-0.52	0.71	0.48	0.52	0.54	0.63	0.51	0.5	0.1	0.41	0.2	0.0	-0.6	-0.58
Cash And Short Term Investments	0.9	-0.01	0.23	0.28	0.93	0.26	-0.88	-0.26	0.95	0.38	0.16		-0.08	0.4	0.32	-0.22	0.59	0.48	0.47	0.18	0.98	-0.06	0.0	0.08	-0.3	-0.11
Net Receivables	-0.1	-0.42	0.62	0.62	-0.01	-0.31	-0.13	0.4	0.04	-0.32	-0.52	-0.08		-0.41	-0.77	-0.25	-0.33	-0.41	-0.43	-0.25	0.05	-0.34	-0.39	0.24	0.27	0.3
Common Stock Shares Outstanding	0.7	0.61	0.03	0.28	0.6	0.92	0.0	-0.85	0.28	0.92	0.71	0.4	-0.41		0.58	0.05	0.81	0.92	0.72	0.89	0.29	0.78	0.25	-0.11	-0.81	-0.75
Non Current Liabilities Total	0.42	0.46	-0.3	-0.24	0.26	0.49	-0.04	-0.75	0.21	0.5	0.48	0.32	-0.77	0.58		-0.09	0.46	0.75	0.86	0.42	0.18	0.56	0.28	-0.41	-0.26	-0.27
Inventory	-0.18	0.03	-0.11	-0.14	-0.15	0.21	0.34	0.13	-0.33	0.09	0.52	-0.22	-0.25	0.05	-0.09		-0.1	-0.1	-0.16	-0.05	-0.21	0.01	-0.1	0.21	-0.1	-0.03
Other Current Assets	0.8	0.4	0.04	0.32	0.74	0.72	-0.24	-0.63	0.47	0.76	0.54	0.59	-0.33	0.81	0.46	-0.1		0.73	0.62	0.66	0.49	0.48	0.14	0.15	-0.76	-0.61
Other Stockholder Equity	0.73	0.61	0.1	0.23	0.6	0.85	-0.09	-0.95	0.35	0.83	0.63	0.48	-0.41	0.92	0.75	-0.1	0.73		0.86	0.81	0.37	0.75	0.11	-0.32	-0.6	-0.51
Total Liab	0.65	0.45	0.13	0.3	0.48	0.68	-0.14	-0.84	0.36	0.66	0.51	0.47	-0.43	0.72	0.86	-0.16	0.62	0.86		0.56	0.35	0.62	0.17	-0.28	-0.41	-0.38
Property Plant And Equipment Gross	0.48	0.58	0.02	0.27	0.4	0.87	0.12	-0.83	0.13	0.8	0.5	0.18	-0.25	0.89	0.42	-0.05	0.66	0.81	0.56		0.11	0.84	0.09	-0.08	-0.7	-0.63
Total Current Assets	0.85	-0.11	0.29	0.33	0.91	0.19	-0.91	-0.15	0.94	0.31	0.1	0.98	0.05	0.29	0.18	-0.21	0.49	0.37	0.35	0.11		-0.19	-0.05	0.14	-0.24	-0.04
Short Term Debt	0.27	0.56	-0.04	0.14	0.11	0.72	0.34	-0.83	-0.07	0.61	0.41	-0.06	-0.34	0.78	0.56	0.01	0.48	0.75	0.62	0.84	-0.19		0.11	-0.25	-0.56	-0.49
Intangible Assets	0.09	-0.07	-0.25	-0.2	0.07	0.07	-0.01	-0.01	0.04	0.41	0.2	0.0	-0.39	0.25	0.28	-0.1	0.14	0.11	0.17	0.09	-0.05	0.11		-0.27	-0.41	-0.7
Accounts Payable	0.04	-0.2	-0.24	0.22	0.12	0.02	-0.1	0.25	0.07	-0.1	0.0	0.08	0.24	-0.11	-0.41	0.21	0.15	-0.32	-0.28	-0.08	0.14	-0.25	-0.27		-0.07	0.04
Common Stock Total Equity	-0.57	-0.44	-0.08	-0.31	-0.54	-0.74	0.01	0.51	-0.22	-0.82	-0.6	-0.3	0.27	-0.81	-0.26	-0.1	-0.76	-0.6	-0.41	-0.7	-0.24	-0.56	-0.41	-0.07		0.82
Common Stock	-0.41	-0.35	0.04	-0.23	-0.36	-0.66	-0.13	0.44	-0.05	-0.83	-0.58	-0.11	0.3	-0.75	-0.27	-0.03	-0.61	-0.51	-0.38	-0.63	-0.04	-0.49	-0.7	0.04	0.82

Click cells to compare fundamentals

Vaxart Account Relationship Matchups

Vaxart fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	37.0M	152.6M	221.2M	153.8M	91.8M	150.6M
Short Long Term Debt Total	2.3M	7.2M	13.0M	21.7M	26.5M	29.3M
Other Current Liab	2.9M	7.6M	5.9M	8.2M	5.6M	9.8M
Total Current Liabilities	9.2M	11.8M	10.8M	17.9M	13.7M	17.6M
Total Stockholder Equity	13.0M	123.4M	187.5M	110.6M	57.8M	89.3M
Property Plant And Equipment Net	2.2M	8.3M	19.8M	41.3M	36.6M	27.5M
Net Debt	(11.2M)	(119.7M)	(130.7M)	(22.3M)	(8.2M)	(8.7M)
Retained Earnings	(116.7M)	(148.9M)	(219.4M)	(327.1M)	(409.6M)	(389.1M)
Cash	13.5M	126.9M	143.7M	44.0M	34.8M	52.2M
Non Current Assets Total	19.4M	24.1M	52.0M	54.4M	46.3M	40.4M
Non Currrent Assets Other	141K	372K	890K	3.6M	926K	879.7K
Cash And Short Term Investments	13.5M	126.9M	166.5M	93.7M	39.7M	61.2M
Net Receivables	3.6M	334K	71K	20K	3.0M	2.9M
Common Stock Shares Outstanding	21.6M	88.3M	121.5M	127.7M	144.8M	152.1M
Liabilities And Stockholders Equity	37.0M	152.6M	221.2M	153.8M	91.8M	150.6M
Non Current Liabilities Total	14.9M	17.4M	22.9M	25.3M	20.3M	27.5M
Other Current Assets	453K	2.4M	5.2M	3.7M	2.8M	4.7M
Other Stockholder Equity	129.6M	272.3M	406.9M	438.0M	467.4M	490.7M
Total Liab	24.1M	29.2M	33.6M	43.3M	34.0M	44.6M
Property Plant And Equipment Gross	2.2M	8.3M	19.8M	15.6M	43.4M	24.7M
Total Current Assets	17.6M	128.5M	169.2M	99.5M	45.5M	43.3M
Accumulated Other Comprehensive Income	(1.6M)	(459K)	(74K)	(299K)	(1K)	(1.1K)
Short Term Debt	841K	2.1M	1.0M	2.3M	6.5M	6.8M
Intangible Assets	17.1M	15.4M	10.6M	5.0M	4.3M	4.1M
Accounts Payable	852K	2.1M	3.9M	5.5M	1.6M	1.5M
Common Stock Total Equity	714K	4.8M	11K	13K	11.7K	11.1K
Common Stock	714K	5K	11K	13K	15K	14.3K
Current Deferred Revenue	4.6M	4.2M	5.1M	2M	(1.1M)	(1.0M)
Other Liab	13.4M	14.9M	10.9M	5.9M	6.7M	7.9M
Net Tangible Assets	13.0M	123.4M	187.5M	110.6M	127.2M	67.4M
Other Assets	141K	372K	890K	3.6M	4.1M	4.3M
Retained Earnings Total Equity	(116.7M)	(148.9M)	(219.4M)	(327.1M)	(294.4M)	(279.7M)
Capital Surpluse	124.8M	272.3M	406.9M	438.0M	503.7M	528.9M
Property Plant Equipment	210K	1.5M	6.6M	15.6M	17.9M	18.8M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Vaxart Stock Analysis

When running Vaxart's price analysis, check to measure Vaxart's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxart is operating at the current time. Most of Vaxart's value examination focuses on studying past and present price action to predict the probability of Vaxart's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxart's price. Additionally, you may evaluate how the addition of Vaxart to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC